Botulinum toxin type A in patients with overactive bladder


Cite item

Full Text

Abstract

The aim of the study was to investigate safety and efficacy of intradetrusor injection of 100 units of botulinum toxin type A in 26 patients with refractory overactive bladder. The diagnostic scheme consisted of 72 h diary, laboratory tests, ultrasound investigation with measurement of residual urine, urodynamic investigation and neurological examination. The patients were divided into 3 groups: 14 patients with idiopathic detrusor overactivity (DO), 9 with neurogenic DO, and 6 with overactive bladder without DO. 100 units of botulinum toxin type A mixed with 20 ml of normal saline were injected into the detrusor sparing the trigone. Clinical and urodynamic evaluations were performed before the injection and 1, 3 and 6 months after it. The patients with idiopathic DO and overactive bladder without DO showed improvement of such clinical symptoms as frequency, urgency, nocturia and urgent incontinence which lasted for at least 6 months. Patients with neurogenic DO had improvement of the clinical symptoms only for one month after treatment. We had no patients who exhibited acute urinary retention or residual urine. Thus, 100 units of botulinum toxin type A injected into the detrusor is an effective, safe and well tolerated treatment for patients with idiopathic DO and overactive bladder without DO in whom an anticholinergic medication has failed.

References

  1. Steawart W. F., Van Rooyen J. B., Cundiff G. W. et al. Prevalence and burden of overactive bladder in the United States. Wld J. Urol. 2003; 20: 327-336.
  2. Milson I., Abrams P., Cardozo L. et al. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. Br. J. Urol. Int. 2001; 87: 760-766.
  3. Мазо Е. Б., Кривобородов Г. Г. Гиперактивный мочевой пузырь. М.: Вече; 2003.
  4. Apostolidis A., Haferkamp A., Aoki K. R. Understanding the role of botulinum toxin A in the treatment of the overactive bladder-more than just muscle relaxation. Eur. Urol. Suppl. 2006; 5: 670-678.
  5. Chapple C., Patel A. Botulinum toxin-new mechanisms, new therapeutic directions? Eur. Urol. 2006; 49: 606-608.
  6. Abrams P., Cardozo L., Fall M. et al. The standardization of terminology of lower urinary tract funcrion: report from Standardization Sub-committee of the International Continence Society. Neurourol. and Urodyn. 2002; 21: 167-178.
  7. Elbadawi A., Yalla S. V., Resnic N. M. Structural basis of geriatric voiding dysfunction. 4: bladder outlet obstruction. J. Urol.(Baltimore) 1993; 150: 1681-1695.
  8. Elbadawi A., Yalla S. V., Resnic N. M. Structural basis of geriatric voiding dysfunction. 3: detrusor overactivity. J. Urol. (Baltimore) 1993; 150: 1668-1680.
  9. Brading A. F. A myogenic basis for the overactive bladder. Urology 1997; 50 (suppl. 6A): 55.
  10. Radziszewski P., Dobronski A., Borkowski A. Treatment of the non-neurogenic storage and voiding disorders with the chemical denervation caused by botulinum toxin type A - a pilot study [abstract]. Neurourol. and Urodyn. 2001; 20: 410-412.
  11. Schurch B., Stohrer M., Kramer G. et al. Botulinum toxin-A for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholenergic drugs.J. Urol. (Baltimore) 2000; 164: 692-697.
  12. Kuo H. C. Urodynamic evidence of effectiveness of butulinum A toxin injection in treatment of detrusor overactivity refractory to anticholenergic agents. Urology 2004; 63: 868-872.
  13. Frenkl T. L., Rackley R. R. Injectable neuromodulatory agents: botulinum toxin therapy. Uriol. Clin. N. Am. 2005; 32: 89-99.
  14. Fowler C. J. Bladder afferents and their role in the overactive bladder. Urology 2002; 59: 37-42.
  15. Gabella G., Davis C. Distribution of afferent axons in the bladder of rats. J. Neurocytol. 1998; 27: 141-155.
  16. Yoshimura N. Bladder afferent pathway and spinal cord injury: possible mechanisms inducing hyperreflexia of urinary bladder. Progr. Neurobiol. 1999; 57: 583-606.
  17. Rajkumar G. N., Small D. R., Mustafa A. W., Conn G. A prospective study to evaluate the safety, tolerability, efficacy and durability of response of intravesical injection of botulinum toxin type A into detrusor muscle in patients with refractory idiopathic detrusor overactive. Br. J. Urol. Int. 2005; 96: 848-852.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies